- 56% OR- Higher clinical response in HRD patients and/or BRCA1 hypermethylation and also in functional HRD harboring low RAD51 foci- Evidence of a single PARPi agent activity beyond gBRCA mutations- Small effective, no randomized control. The gene discussed is RAD51; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.